Evelo Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.5
- Today's High:
- $7.25
- Open Price:
- $6.5
- 52W Low:
- $0.099
- 52W High:
- $3.29
- Prev. Close:
- $6.51
- Volume:
- 102150
Company Statistics
- Market Cap.:
- $12.99 million
- Book Value:
- -0.247
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -129.75%
- Return on Equity TTM:
- -6232.76%
Company Profile
Evelo Biosciences Inc had its IPO on 2018-05-09 under the ticker symbol EVLO.
The company operates in the Healthcare sector and Biotechnology industry. Evelo Biosciences Inc has a staff strength of 66 employees.
Stock update
Shares of Evelo Biosciences Inc opened at $6.5 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.5 - $7.25, and closed at $6.7.
This is a +2.92% increase from the previous day's closing price.
A total volume of 102,150 shares were traded at the close of the day’s session.
In the last one week, shares of Evelo Biosciences Inc have increased by +0.75%.
Evelo Biosciences Inc's Key Ratios
Evelo Biosciences Inc has a market cap of $12.99 million, indicating a price to book ratio of 22.3128 and a price to sales ratio of 0.
In the last 12-months Evelo Biosciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-102640000. The EBITDA ratio measures Evelo Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Evelo Biosciences Inc’s operating margin was 0% while its return on assets stood at -129.75% with a return of equity of -6232.76%.
In Q1, Evelo Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Evelo Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.93 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evelo Biosciences Inc’s profitability.
Evelo Biosciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.7139. Its price to sales ratio in the trailing 12-months stood at 0.
Evelo Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $41.97 million
- Total Liabilities
- $57.25 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $12000
- Dividend Payout Ratio
- 0%
Evelo Biosciences Inc ended 2024 with $41.97 million in total assets and $0 in total liabilities. Its intangible assets were valued at $41.97 million while shareholder equity stood at $-27388000.00.
Evelo Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $57.25 million in other current liabilities, 111000.00 in common stock, $-554563000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $27.47 million and cash and short-term investments were $27.47 million. The company’s total short-term debt was $46,117,000 while long-term debt stood at $0.
Evelo Biosciences Inc’s total current assets stands at $30.08 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.51 million and inventory worth $0.
In 2024, Evelo Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $12000.
Comparatively, Evelo Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $6.7
- 52-Week High
- $3.29
- 52-Week Low
- $0.099
- Analyst Target Price
- $1.4
Evelo Biosciences Inc stock is currently trading at $6.7 per share. It touched a 52-week high of $3.29 and a 52-week low of $3.29. Analysts tracking the stock have a 12-month average target price of $1.4.
Its 50-day moving average was $7.42 and 200-day moving average was $12.3 The short ratio stood at 0.35 indicating a short percent outstanding of 0%.
Around 12.7% of the company’s stock are held by insiders while 8365.9% are held by institutions.
Frequently Asked Questions About Evelo Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.